{"id":"https://openalex.org/W2568074908","doi":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","title":"P57 The cost-consequence of fluticasone furoate/vilanterol 100/25 MCG in the uk using the results from the COPD salford lung study","display_name":"P57 The cost-consequence of fluticasone furoate/vilanterol 100/25 MCG in the uk using the results from the COPD salford lung study","publication_year":2016,"publication_date":"2016-11-15","ids":{"openalex":"https://openalex.org/W2568074908","doi":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","mag":"2568074908"},"language":"en","primary_location":{"id":"doi:10.1136/thoraxjnl-2016-209333.200","doi":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","is_oa":true,"landing_page_url":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","pdf_url":"https://thorax.bmj.com/content/thoraxjnl/71/Suppl_3/A114.full.pdf","source":{"id":"https://openalex.org/S106546978","display_name":"Thorax","issn_l":"0040-6376","issn":["0040-6376","1468-3296"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Thorax","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://thorax.bmj.com/content/thoraxjnl/71/Suppl_3/A114.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032612460","display_name":"MT Driessen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"MT Driessen","raw_affiliation_strings":["GlaxoSmithKline, Brentford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Brentford, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033213600","display_name":"S Barnfather","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S Barnfather","raw_affiliation_strings":["GlaxoSmithKline, Stockley Park, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Stockley Park, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045227711","display_name":"PJ Mulley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"PJ Mulley","raw_affiliation_strings":["GlaxoSmithKline, Brentford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Brentford, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047445014","display_name":"Isabelle H. Boucot","orcid":"https://orcid.org/0000-0003-0410-4969","observed_orcids":["https://orcid.org/0000-0003-0410-4969"]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"I\u2009I Boucot","raw_affiliation_strings":["GlaxoSmithKline, Brentford, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Brentford, UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067941899","display_name":"TJ Ignacio","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210094451","display_name":"Pharmerit (Netherlands)","ror":"https://ror.org/00ntr9f13","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210094451","https://openalex.org/I4210134090"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"T Ignacio","raw_affiliation_strings":["Pharmerit International, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit International, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I4210094451"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036545592","display_name":"Gijs van de Wetering","orcid":"https://orcid.org/0009-0001-6498-2950","observed_orcids":["https://orcid.org/0009-0001-6498-2950"]},"institutions":[{"id":"https://openalex.org/I4210094451","display_name":"Pharmerit (Netherlands)","ror":"https://ror.org/00ntr9f13","country_code":"NL","type":"company","lineage":["https://openalex.org/I4210094451","https://openalex.org/I4210134090"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"G van de Wetering","raw_affiliation_strings":["Pharmerit International, Rotterdam, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmerit International, Rotterdam, The Netherlands","institution_ids":["https://openalex.org/I4210094451"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":"Suppl 3","first_page":"A114","last_page":"A115"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.7968999743461609,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10143","display_name":"Chronic Obstructive Pulmonary Disease (COPD) Research","score":0.7968999743461609,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.1964000016450882,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11651","display_name":"Inhalation and Respiratory Drug Delivery","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fluticasone-furoate-vilanterol","display_name":"fluticasone furoate/vilanterol","score":0.9179999828338623},{"id":"https://openalex.org/keywords/chronic-obstructive-pulmonary-disease","display_name":"chronic obstructive pulmonary disease","score":0.8569999933242798},{"id":"https://openalex.org/keywords/cost-consequence-analysis","display_name":"cost-consequence analysis","score":0.8790000081062317},{"id":"https://openalex.org/keywords/acute-exacerbation-of-copd","display_name":"COPD exacerbations","score":0.8330000042915344},{"id":"https://openalex.org/keywords/usual-care","display_name":"usual care","score":0.7429999709129333},{"id":"https://openalex.org/keywords/drug-costs","display_name":"drug costs","score":0.5600000023841858},{"id":"https://openalex.org/keywords/cost-reduction","display_name":"cost reduction","score":0.7450000047683716},{"id":"https://openalex.org/keywords/ics-laba","display_name":"ICS/LABA","score":0.7570000290870667},{"id":"https://openalex.org/keywords/economic-impact","display_name":"economic impact","score":0.35499998927116394}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9267163276672363},{"id":"https://openalex.org/C2777014857","wikidata":"https://www.wikidata.org/wiki/Q1383410","display_name":"Exacerbation","level":2,"score":0.834458589553833},{"id":"https://openalex.org/C2776780178","wikidata":"https://www.wikidata.org/wiki/Q199804","display_name":"COPD","level":2,"score":0.8306068778038025},{"id":"https://openalex.org/C2779028295","wikidata":"https://www.wikidata.org/wiki/Q8564098","display_name":"Fluticasone propionate","level":3,"score":0.8277032375335693},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.6146050095558167},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5703518986701965},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5482592582702637},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.474581241607666},{"id":"https://openalex.org/C2781212218","wikidata":"https://www.wikidata.org/wiki/Q1002165","display_name":"Fluticasone","level":3,"score":0.4634195864200592},{"id":"https://openalex.org/C67774102","wikidata":"https://www.wikidata.org/wiki/Q614132","display_name":"Number needed to treat","level":4,"score":0.4537234604358673},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.43081557750701904},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.38866063952445984},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.38704872131347656},{"id":"https://openalex.org/C2776804153","wikidata":"https://www.wikidata.org/wiki/Q210420","display_name":"Corticosteroid","level":2,"score":0.25788170099258423},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.2336968183517456},{"id":"https://openalex.org/C82789193","wikidata":"https://www.wikidata.org/wiki/Q2142611","display_name":"Relative risk","level":3,"score":0.17212536931037903},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.07936877012252808},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/thoraxjnl-2016-209333.200","doi":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","is_oa":true,"landing_page_url":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","pdf_url":"https://thorax.bmj.com/content/thoraxjnl/71/Suppl_3/A114.full.pdf","source":{"id":"https://openalex.org/S106546978","display_name":"Thorax","issn_l":"0040-6376","issn":["0040-6376","1468-3296"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Thorax","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1136/thoraxjnl-2016-209333.200","doi":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","is_oa":true,"landing_page_url":"https://doi.org/10.1136/thoraxjnl-2016-209333.200","pdf_url":"https://thorax.bmj.com/content/thoraxjnl/71/Suppl_3/A114.full.pdf","source":{"id":"https://openalex.org/S106546978","display_name":"Thorax","issn_l":"0040-6376","issn":["0040-6376","1468-3296"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Thorax","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2568074908.pdf","grobid_xml":"https://content.openalex.org/works/W2568074908.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2570667134","https://openalex.org/W2891611748","https://openalex.org/W3143595100","https://openalex.org/W2766467225","https://openalex.org/W2552032908","https://openalex.org/W2765532207","https://openalex.org/W2909257760","https://openalex.org/W2970848160","https://openalex.org/W3028481585","https://openalex.org/W4360875016"],"abstract_inverted_index":{"Introduction":[0],"To":[1],"support":[2],"clinicians":[3,328],"and":[4,57,63,108,131,220,227,247,257,281,329],"healthcare":[5],"organisations":[6],"in":[7,26,86,90,116,124,132,137,155,172,222,312,318],"their":[8],"decision":[9],"making":[10],"on":[11],"Chronic":[12],"Obstructive":[13],"Pulmonary":[14],"Disease":[15],"(COPD)":[16],"related":[17],"care,":[18,98],"there":[19],"is":[20,41,272],"a":[21,156,181,293],"need":[22],"for":[23,210,292,327],"studies":[24],"conducted":[25,54],"patient":[27],"populations":[28],"which":[29],"are":[30,325],"representative":[31],"of":[32,65,106,152,165,193,204,288,295],"everyday":[33,92,303],"clinical":[34,93,305],"practice.":[35],"The":[36,51,144,178],"Salford":[37],"Lung":[38],"Study":[39],"(SLS)":[40],"an":[42,91,173,302],"open":[43],"label":[44],"prospective":[45],"randomised":[46],"controlled":[47],"effectiveness":[48,62],"trial":[49],"(RCT).":[50],"study":[52,146],"was":[53,185],"between":[55],"2012":[56],"2015.":[58],"SLS":[59],"investigated":[60],"the":[61,103,117,148,191,211,218,223,238],"safety":[64],"initiating":[66],"treatment":[67,83],"with":[68,77,79,88,96,134,168,270,277,298,310,314],"once":[69],"daily":[70],"fluticasone":[71],"furoate/vilanterol":[72],"100/25":[73],"microgram":[74],"(FF/VI)":[75],"compared":[76],"continuing":[78],"usual":[80,97,229,255,268,308],"COPD":[81,89,169,258,279,315],"maintenance":[82],"(usual":[84],"care)":[85],"patients":[87,133,167,297,313],"setting.":[94],"Compared":[95],"FF/VI":[99,194,226,271,311],"statistically":[100],"significantly":[101],"reduced":[102,278],"annual":[104,202,249,286,320],"rate":[105],"moderate":[107],"severe":[109,264],"exacerbations":[110,206],"by":[111],"8.41%":[112],"(NNT":[113],"=":[114,129,142],"7)":[115],"intention":[118],"to":[119,199,274],"treat":[120],"population":[121,213,294],"(\u22651":[122],"exacerbation":[123,136,259,282],"previous":[125,138],"3":[126],"y;":[127,140],"n":[128,141],"2799),":[130],"\u22651":[135],"1":[139],"2269).":[143],"current":[145],"estimates":[147],"potential":[149],"economic":[150],"impact":[151],"these":[153],"results":[154,324],"typical":[157],"local":[158],"UK":[159,244,304],"payer":[160],"environment.":[161],"Methods":[162],"A":[163],"total":[164],"1000":[166,296],"were":[170,214,235,241,290],"included":[171,221],"Excel":[174],"based":[175],"cost-consequence":[176],"model.":[177],"model":[179,224],"has":[180],"1-year":[182],"time-horizon.":[183],"It":[184],"assumed":[186],"that":[187],"within":[188],"one":[189],"year":[190],"use":[192],"would":[195],"increase":[196],"from":[197,217,237,243],"5%":[198],"20%.":[200],"Mean":[201],"rates":[203],"moderate/severe":[205],"after":[207],"twelve":[208],"months":[209],"ITT":[212],"directly":[215],"obtained":[216,242,291],"RCT":[219],"(1.50":[225],"1.64":[228],"care).":[230],"Serious":[231],"adverse":[232],"events":[233],"(SAEs)":[234],"excluded":[236],"analysis.":[239],"Costs":[240],"public":[245],"sources":[246],"encompassed":[248],"drug":[250],"costs":[251,261],"(\u00a3268":[252],"FF/VI;":[253],"\u00a3491":[254],"care),":[256],"management":[260,283],"(moderate":[262],"\u00a3114;":[263],"\u00a32,053).":[265],"Results":[266],"Substituting":[267],"care":[269,309,331],"likely":[273],"be":[275],"associated":[276],"medication":[280],"costs.":[284],"Total":[285],"savings":[287],"\u00a334,000":[289],"COPD.":[299],"Conclusion":[300],"In":[301],"setting,":[306],"substituting":[307],"can":[316],"result":[317],"substantial":[319],"cost":[321],"savings.":[322],"These":[323],"relevant":[326],"health":[330],"organisations.":[332]},"counts_by_year":[{"year":2018,"cited_by_count":1}],"updated_date":"2026-09-25T08:18:29.962427","created_date":"2017-01-13T00:00:00"}